Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial-Reference-Cited by-同舟云学术

Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial

Published:2022-12 Issue:5 Volume:114 Page:849-855
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Baker S.,Mou B.,Jiang W.,Liu M.,Bergman A.M.,Schellenberg D.,Alexander A.S.,Carolan H.,Atrchian S.,Berrang T.,Bang A.,Chng N.,Matthews Q.,Tyldesley S.,Olson R.A.

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference16 articles.

1. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial;Palma;Lancet,2019

2. Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation;Guckenberger;Lancet Oncol,2020

3. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document;Lievens;Radiother Oncol,2020

4. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions;Li;Ann Palliat Med,2021

5. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic cancers: Where will the evidence lead?;Al-Shafa;Front Oncol,2019

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review;Future Oncology;2024-09-11

2. Stereotactic radiotherapy for liver oligometastases: a pooled analysis following the estro/eortc consensus recommendations;Clinical & Experimental Metastasis;2024-07-17

3. Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer;Radiotherapy and Oncology;2024-07

4. Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial;International Journal of Radiation Oncology*Biology*Physics;2024-04

5. Stereotactic body radiotherapy as a viable treatment on extracranial oligometastases in melanoma patients: a retrospective multicentric study;Frontiers in Oncology;2024-03-05